Wall Street Zen Upgrades XWELL (NASDAQ:XWEL) to “Sell”

XWELL (NASDAQ:XWEL) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of XWELL in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, XWELL currently has a consensus rating of “Sell”.

XWELL Price Performance

Shares of NASDAQ:XWEL opened at $1.19 on Friday. The company has a market capitalization of $6.87 million, a price-to-earnings ratio of -0.23 and a beta of 0.96. The business’s 50-day moving average is $1.01 and its 200-day moving average is $0.84. XWELL has a 1 year low of $0.26 and a 1 year high of $2.20.

XWELL (NASDAQ:XWEL) last issued its earnings results on Wednesday, April 1st. The company reported ($3.29) EPS for the quarter. XWELL had a negative net margin of 58.17% and a negative return on equity of 352.37%. The firm had revenue of $7.15 million during the quarter.

About XWELL

XWELL, Inc provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels.